ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $39.00 at HC Wainwright

Posted by Chris Copeland on Jan 23rd, 2025

ArriVent BioPharma (NASDAQ:AVBP – Free Report) had its price target hoisted by HC Wainwright from $36.00 to $39.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

ArriVent BioPharma Trading Up 5.2 %

AVBP opened at $26.63 on Wednesday. The company has a 50 day simple moving average of $27.00 and a two-hundred day simple moving average of $25.96. ArriVent BioPharma has a 1-year low of $14.35 and a 1-year high of $36.37.

Institutional Investors Weigh In On ArriVent BioPharma

Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers boosted its stake in shares of ArriVent BioPharma by 30.1% in the second quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock worth $236,000 after acquiring an additional 2,942 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in ArriVent BioPharma during the 3rd quarter valued at approximately $240,000. SG Americas Securities LLC bought a new stake in shares of ArriVent BioPharma during the third quarter valued at approximately $280,000. JPMorgan Chase & Co. lifted its holdings in shares of ArriVent BioPharma by 183.2% in the third quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company’s stock worth $292,000 after buying an additional 8,050 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of ArriVent BioPharma by 168.9% during the third quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock worth $384,000 after acquiring an additional 10,269 shares during the last quarter. Hedge funds and other institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.